Histology News and Research

RSS

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.

11 Feb 2015

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer.

20 Jan 2015

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer.

11 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers from QUT's Institute of Health and Biomedical Innovation developing eye tests to assess diabetic neuropathy and pave the way for earlier treatment are key partners in a consortium awarded $US1.1 million from the leading American medical research agency.

5 Dec 2014

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

24 Nov 2014

PORT can improve survival for non-small cell lung cancer patients

Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Partial nephrectomy efficacious for clinical T2 renal masses

Survival outcomes and overall complication rates of partial nephrectomy for clinical T2 renal masses are comparable to those of radical nephrectomy when the pathological staging, histology and grading of the tumours are similar, researchers report.

30 Oct 2014

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers.

22 Oct 2014

Six platinum cycles no better than four for advanced NSCLC

Six cycles of adjuvant platinum-based chemotherapy is no better than three or four cycles for patients with advanced non-small-cell lung cancer, meta-analysis results suggests.

22 Oct 2014

New research suggests that exposure to aluminium may reduce male fertility

And the team of scientists, at the universities of Lyon and Saint-Etienne in France and Keele in the UK, found that the higher the aluminium, the lower sperm count.

21 Oct 2014

UCSD researchers define epidemiology of gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine.

8 Oct 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG).

24 Sep 2014

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

17 Sep 2014